280 related articles for article (PubMed ID: 32935346)
1. Pharmacologic treatment of GERD: Where we are now, and where are we going?
Scarpignato C; Hongo M; Wu JCY; Lottrup C; Lazarescu A; Stein E; Hunt RH
Ann N Y Acad Sci; 2020 Dec; 1482(1):193-212. PubMed ID: 32935346
[TBL] [Abstract][Full Text] [Related]
2. Potassium-competitive acid blockers and gastroesophageal reflux disease.
Leowattana W; Leowattana T
World J Gastroenterol; 2022 Jul; 28(28):3608-3619. PubMed ID: 36161043
[TBL] [Abstract][Full Text] [Related]
3. Acid suppression therapy: where do we go from here?
Scarpignato C; Pelosini I; Di Mario F
Dig Dis; 2006; 24(1-2):11-46. PubMed ID: 16699262
[TBL] [Abstract][Full Text] [Related]
4. Gastrointestinal pharmacology: practical tips for the esophagologist.
Scarpignato C; Sloan JA; Wang DH; Hunt RH
Ann N Y Acad Sci; 2020 Dec; 1481(1):90-107. PubMed ID: 32822080
[TBL] [Abstract][Full Text] [Related]
5. Novel Therapies for Gastroesophageal Reflux Disease: Beyond Proton Pump Inhibitors.
Shibli F; Kitayama Y; Fass R
Curr Gastroenterol Rep; 2020 Mar; 22(4):16. PubMed ID: 32185589
[TBL] [Abstract][Full Text] [Related]
6. Pharmacologic management of gastroesophageal reflux disease.
Ramakrishnan A; Katz PO
Curr Gastroenterol Rep; 2002 Jun; 4(3):218-24. PubMed ID: 12010622
[TBL] [Abstract][Full Text] [Related]
7. Drugs, bugs, and esophageal pH profiles.
Robinson M
Yale J Biol Med; 1999; 72(2-3):169-72. PubMed ID: 10780578
[TBL] [Abstract][Full Text] [Related]
8. Patterns of proton pump inhibitor utilization in gastroesophageal reflux disease and the effect of restrictions on reimbursement: a nationwide prescription database study.
Jonasson C; Tvete IF; Hatlebakk JG
Scand J Gastroenterol; 2013 Sep; 48(9):1010-7. PubMed ID: 23859491
[TBL] [Abstract][Full Text] [Related]
9. Short-Term Symptomatic Relief in Gastroesophageal Reflux Disease: A Comparative Study of Esomeprazole and Vonoprazan.
Sakurai K; Suda H; Fujie S; Takeichi T; Okuda A; Murao T; Hasuda K; Hirano M; Ito K; Tsuruta K; Hattori M
Dig Dis Sci; 2019 Mar; 64(3):815-822. PubMed ID: 30415407
[TBL] [Abstract][Full Text] [Related]
10. Evolving drugs in gastroesophageal reflux disease: pharmacologic treatment beyond proton pump inhibitors.
Johnson DA; Levy BH
Expert Opin Pharmacother; 2010 Jun; 11(9):1541-8. PubMed ID: 20450445
[TBL] [Abstract][Full Text] [Related]
11. Vonoprazan versus proton-pump inhibitors for healing gastroesophageal reflux disease: A systematic review.
Miyazaki H; Igarashi A; Takeuchi T; Teng L; Uda A; Deguchi H; Higuchi K; Tango T
J Gastroenterol Hepatol; 2019 Aug; 34(8):1316-1328. PubMed ID: 30883868
[TBL] [Abstract][Full Text] [Related]
12. Systematic review with network meta-analysis: indirect comparison of the efficacy of vonoprazan and proton-pump inhibitors for maintenance treatment of gastroesophageal reflux disease.
Miwa H; Igarashi A; Teng L; Uda A; Deguchi H; Tango T
J Gastroenterol; 2019 Aug; 54(8):718-729. PubMed ID: 30919071
[TBL] [Abstract][Full Text] [Related]
13. The potential role of potassium-competitive acid blockers in the treatment of gastroesophageal reflux disease.
Scarpignato C; Hunt RH
Curr Opin Gastroenterol; 2019 Jul; 35(4):344-355. PubMed ID: 31045597
[TBL] [Abstract][Full Text] [Related]
14. Mucosal Protective Compounds in the Treatment of Gastroesophageal Reflux Disease. A Position Paper Based on Evidence of the Romanian Society of Neurogastroenterology.
Surdea-Blaga T; Băncilă I; Dobru D; Drug V; Frățilă O; Goldiș A; Grad SM; Mureșan C; Nedelcu L; Porr PJ; Sporea I; Dumitrascu DL
J Gastrointestin Liver Dis; 2016 Dec; 25(4):537-546. PubMed ID: 27981311
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of Vonoprazan, a Novel Potassium-Competitive Acid Blocker, in Patients with Proton Pump Inhibitor-Refractory Acid Reflux.
Akiyama J; Hosaka H; Kuribayashi S; Moriyasu S; Hisada Y; Okubo H; Watanabe K; Imbe K; Nagata N; Kojima Y; Yokoi C; Uemura N; Shimoyama Y; Kawamura O; Yamada M; Kusano M
Digestion; 2020; 101(2):174-183. PubMed ID: 30897577
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of Vonoprazan for Gastroesophageal Reflux Symptoms in Patients with Proton Pump Inhibitor-resistant Non-erosive Reflux Disease.
Niikura R; Yamada A; Hirata Y; Hayakawa Y; Takahashi A; Shinozaki T; Takeuchi Y; Fujishiro M; Koike K
Intern Med; 2018 Sep; 57(17):2443-2450. PubMed ID: 29607951
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of gastroesophageal reflux disease symptoms and effects of esomeprazole on the quality of life related to reflux and dyspepsia in patients on maintenance hemodialysis.
Namikoshi T; Harada K; Hatta H; Tokura T; Oshiro Y; Nishizaki T; Obata T; Mori M; Fueki T; Fujimoto S; Haruna Y; Kuwabara A; Yorimitsu D; Ihoriya C; Kadoya H; Itano S; Fujimoto Y; Komai N; Sasaki T; Kashihara N
Clin Exp Nephrol; 2016 Feb; 20(1):134-42. PubMed ID: 26026991
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic choices in reflux disease: defining the criteria for selecting a proton pump inhibitor.
Freston JW
Am J Med; 2004 Sep; 117 Suppl 5A():14S-22S. PubMed ID: 15478848
[TBL] [Abstract][Full Text] [Related]
19. Factors Associated with Potassium-Competitive Acid Blocker Non-Response in Patients with Proton Pump Inhibitor-Refractory Gastroesophageal Reflux Disease.
Okuyama M; Nakahara K; Iwakura N; Hasegawa T; Oyama M; Inoue A; Ishizu H; Satoh H; Fujiwara Y
Digestion; 2017; 95(4):281-287. PubMed ID: 28501868
[TBL] [Abstract][Full Text] [Related]
20. Vonoprazan fumarate for the management of acid-related diseases.
Martinucci I; Blandizzi C; Bodini G; Marabotto E; Savarino V; Marchi S; de Bortoli N; Savarino E
Expert Opin Pharmacother; 2017 Aug; 18(11):1145-1152. PubMed ID: 28657473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
